Similar articles

• [Cardiovascular risk factors associated with antiretroviral therapy].

  Pérez-Camacho I, Camacho A, Torre-Cisneros J, Rivero A. Pérez-Camacho I, et al. Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:24-32. doi: 10.1016/S0213-005X(09)73442-1. Enferm Infecc Microbiol Clin. 2009. PMID: 20172412 Review. Spanish.
• Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy.

  Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM. Sereti I, et al. AIDS. 2001 Jan 5;15(1):138-40. doi: 10.1097/00002030-200101050-00026. AIDS. 2001. PMID: 11192862 No abstract available.
• Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.

  Deeks SG, Martin JN. Deeks SG, et al. AIDS. 2001 Jan 5;15(1):117-9. doi: 10.1097/00002030-200101050-00017. AIDS. 2001. PMID: 11192853 No abstract available.
• Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.

  Nerad JL, Kessler HA. Nerad JL, et al. Clin Infect Dis. 2001 Jun 1;32(11):1635-6. doi: 10.1086/320528. Epub 2001 Apr 30. Clin Infect Dis. 2001. PMID: 11340537
• HIV, HAART, and hyperlipidemia: balancing the effects.

  Sherer R. Sherer R. J Acquir Immune Defic Syndr. 2003 Oct 1;34 Suppl 2:S123-9. doi: 10.1097/00126334-200310012-00005. J Acquir Immune Defic Syndr. 2003. PMID: 14703941 Review. No abstract available.